Sector News

Bristol-Myers selling Ireland plant to South Korean company

June 16, 2017
Life sciences

Bristol-Myers Squibb, which is shifting its focus toward biologics manufacturing, will unload an API plant in Ireland to a South Korean company that has aspirations of becoming a big deal in contract manufacturing.

The U.S. drugmaker said today that it will sell its plant in Swords to SK Biotek, a unit of South Korea’s third largest conglomerate, SK Holdings. SK has been a BMS ingredient supplier for a decade.

The two kept terms under wraps except to say the deal should close in Q4 and that SK will continue to produce the products BMS now makes at the plant, which includes the API for Bristol-Myers Squibb and Pfizer’s anticoagulant Eliquis. SK Biotek will take on about 300 workers at the facility, while some will transfer to jobs in Dublin, a BMS spokesman said in an email.

SK Biotek, the first South Korean company to set up shop in Ireland, will use the BMS plant as a base for its burgeoning contract development and manufacturing business. It plans to add marketing and research and development operations at the site, as well as spend money on upgrades to boost capacity.

“This transaction is an important step to achieve our goal of becoming a leading global CDMO,” SK Biotek CEO Junku Park said in a statement.

SK Holdings, which has revenues that top $120 billion, has decided that contract pharma manufacturing is a natural offshoot of its chemical and ingredient businesses and has identified it as a growth driver for the company. It has four plants in South Korea, according to its website, and SK Biotek had 2015 revenues of KRW 75.5 billion ($6.6 million). It says it expects the unit to reach KRW 130 billion in sales this year. It has said it would like to someday rival CDMOs like Lonza and Boehringer Ingelheim.

Last year, SK Holdings indicated it was working on a couple of deals, worth about $500 million each, to buy API sites in the U.S. and Europe.

Like other big drugmakers, BMS has been scaling back in small-molecule production. In 2015, it closed an API plant at Cruiserath in North County Dublin and shut down a production line at the plant in Swords. That has happened as its pipeline of products shifted toward biologic drugs. It is building a $900 million, 320,000-square-foot biologics plant adjacent to a bulk manufacturing facility in Dublin.

“Today’s agreement is an important step in the ongoing evolution of our manufacturing network to support the company’s innovative portfolio,” Lou Schmukler, BMS president of global product development and supply, said in a statement.

By Eric Palmer

Source: Fierce Biotech

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend